Might be an opportunity @ lower fibs retracement from current 4.12 area-
@ 38.6% fib retracement @ 3.2
@ 61.8% retracement of 2.27 and
@ 78.6% @ 1.61. ....
In the Oct/Nov. dilution of 4.1 million shares @ 4.3$ -- NVAX retraced down to 2.73 area from 6$ ~ 61.8% fibs retracement to 2.73 area -- (55% hair cut from 6$) before bounced to 4.88 area -- those holders prolly took the opportunity to dump at above 4.3$...
Comes January who knows - but looks like NVAX mgmt want to pay up for some new year bonuses!
So watch out those fibs levels @ 38.6% and 61.8% retracements
Cheers!
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Novavax files $100 mln equity shelf offering
Wed Dec 21, 2005 04:31 PM ET
WASHINGTON, Dec 21 (Reuters) - Biotech company Novavax Inc. (NVAX.O: Quote, Profile, Research) on Wednesday said it may periodically sell up to $100 million in common and preferred stock and warrants.
The company said it plans to use the proceeds for general corporate purposes, which may include clinical development of avian and seasonal flu vaccines, internal research and development, expansion of facilities and general working capital.
If filed a shelf registration statement with the U.S. Securities and Exchange Commission. Under a shelf registration, a company may sell securities in one or more separate offerings with the size, price and terms to be determined at the time of sale.
@ 38.6% fib retracement @ 3.2
@ 61.8% retracement of 2.27 and
@ 78.6% @ 1.61. ....
In the Oct/Nov. dilution of 4.1 million shares @ 4.3$ -- NVAX retraced down to 2.73 area from 6$ ~ 61.8% fibs retracement to 2.73 area -- (55% hair cut from 6$) before bounced to 4.88 area -- those holders prolly took the opportunity to dump at above 4.3$...
Comes January who knows - but looks like NVAX mgmt want to pay up for some new year bonuses!
So watch out those fibs levels @ 38.6% and 61.8% retracements
Cheers!
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Novavax files $100 mln equity shelf offering
Wed Dec 21, 2005 04:31 PM ET
WASHINGTON, Dec 21 (Reuters) - Biotech company Novavax Inc. (NVAX.O: Quote, Profile, Research) on Wednesday said it may periodically sell up to $100 million in common and preferred stock and warrants.
The company said it plans to use the proceeds for general corporate purposes, which may include clinical development of avian and seasonal flu vaccines, internal research and development, expansion of facilities and general working capital.
If filed a shelf registration statement with the U.S. Securities and Exchange Commission. Under a shelf registration, a company may sell securities in one or more separate offerings with the size, price and terms to be determined at the time of sale.
